"brandDrugName","originalDrugName","drugId","targetIds","interactorIds","sponsor","properties","therapeuticArea","indication","diseaseName","diseaseIds","diseaseClass","reviewType","yearApproval"
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000160014","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000160014","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000160014","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000136573","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000136573","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000136573","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000136573","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000136573","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000100591","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000100591","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000100591","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000124942","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000124942","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000124942","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000124942","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000124942","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000124942","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Parsabiv","Etelcalcetide","CHEMBL3545184","ENSG00000036828","ENSG00000036828","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017
"Parsabiv","Etelcalcetide","CHEMBL3545184","ENSG00000036828","ENSG00000036828","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017
"Parsabiv","Etelcalcetide","CHEMBL3545184","ENSG00000036828","ENSG00000036828","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017
"Parsabiv","Etelcalcetide","CHEMBL3545184","ENSG00000036828","ENSG00000036828","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017
"Parsabiv","Etelcalcetide","CHEMBL3545184","ENSG00000036828","ENSG00000036828","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017
"Parsabiv","Etelcalcetide","CHEMBL3545184","ENSG00000036828","ENSG00000036828","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017
"Parsabiv","Etelcalcetide","CHEMBL3545184","ENSG00000036828","ENSG00000036828","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017
"Parsabiv","Etelcalcetide","CHEMBL3545184","ENSG00000036828","ENSG00000036828","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017
"Parsabiv","Etelcalcetide","CHEMBL3545184","ENSG00000036828","ENSG00000036828","Amgen/Kai Pharmaceuticals","Calcium-sensing receptor agonist","Other indication","Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis","hyperparathyroidism","EFO_0008506","Not serious","S",2017
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113070","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113070","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113070","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113070","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113070","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113070","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000182718","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000182718","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000182718","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113070","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113070","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113070","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000107317","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000107317","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000107317","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000163235","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000163235","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000163235","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000182636","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000182636","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000182636","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000100170","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000100170","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000100170","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000104756","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000104756","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000104756","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000204410","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000204410","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000043462","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000043462","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000043462","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000043462","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000043462","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000043462","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000157764","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000157764","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000157764","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000157764","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000157764","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000157764","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000157764","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000157764","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000157764","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000157764","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000157764","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000157764","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000157764","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000157764","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000157764","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000157764","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000157764","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000157764","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000110651","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000110651","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000110651","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000198909","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000198909","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000198909","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000106211","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000106211","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000106211","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000106211","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000106211","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000106211","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000126561","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000126561","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000126561","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000012061","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000012061","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000012061","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000067606","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000067606","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000067606","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000126561","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000126561","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000126561","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000067606","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000067606","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000067606","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000081237","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000081237","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000081237","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000081237","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000081237","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000110395","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000110395","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000110395","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000110395","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000110395","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000081237","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000081237","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000081237","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000081237","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000081237","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000110395","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000110395","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000110395","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000110395","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000110395","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000115415","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000115415","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000115415","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000115415","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000115415","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000115415","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000081237","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000081237","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000081237","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000081237","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000081237","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000110395","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000110395","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000110395","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000110395","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000110395","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000115415","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000115415","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000115415","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000143322","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000143322","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000143322","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000143322","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000143322","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000143322","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000143322","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000143322","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000143322","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000143322","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000131016","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000131016","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000131016","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000131016","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000131016","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000131016","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000130340","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000130340","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000130340","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000112715","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000112715","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000112715","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000134308","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000134308","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000134308","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000127329","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000127329","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000127329","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000127329","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000127329","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000138363","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000138363","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000138363","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000104341","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000104341","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000104341","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000104341","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000104341","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000127329","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000127329","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000127329","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000127329","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000127329","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000138363","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000138363","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000138363","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000104341","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000104341","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000104341","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000104341","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000104341","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000127329","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000127329","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000127329","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000127329","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000127329","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000061273","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000061273","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000061273","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000151491","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000151491","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000151491","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000061273","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000061273","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000061273","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000079308","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000079308","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000079308","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000079308","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000158092","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000158092","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000158092","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000158092","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000158092","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000058262","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000058262","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000058262","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000158092","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000158092","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000158092","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000158092","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000158092","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000186868","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000186868","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000186868","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000185338","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000185338","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000115145","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000115145","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000115145","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000197943","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000197943","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000197943","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000197943","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000197943","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000154556","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000154556","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000154556","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000185338","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000185338","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000197943","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000197943","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000197943","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000197943","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000197943","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000154556","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000154556","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000154556","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000091831","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000091831","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000091831","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000091831","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000091831","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000091831","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000091831","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000091831","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000091831","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000091831","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000091831","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000091831","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000091831","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000091831","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000091831","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000196961","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000196961","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000196961","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000079805","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000079805","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168036","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168036","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168036","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000115290","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000115290","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000140575","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000140575","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000140575","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168036","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168036","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168036","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000140575","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000140575","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000140575","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168036","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168036","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168036","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168036","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168036","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168036","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000115290","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000115290","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168036","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168036","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168036","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000124207","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000124207","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000124207","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000006125","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000006125","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000006125","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000006125","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000006125","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000006125","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000204388","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000204388","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000204388","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000117461","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000117461","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000117461","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000117461","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000117461","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000171132","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000171132","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000171132","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000117152","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000117152","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000117152","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000117461","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000117461","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000117461","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000117461","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000117461","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000171132","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000171132","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000171132","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000117461","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000117461","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000117461","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000117461","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000117461","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000171132","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000171132","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000171132","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000171132","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000171132","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000171132","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000096384","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000096384","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000096384","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000096384","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000096384","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000096384","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000096384","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000096384","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000096384","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000096384","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000096384","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000096384","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111816","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111816","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111816","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111816","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111816","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111816","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111816","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111816","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111816","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000146648","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146648","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146648","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146648","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000146648","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000174791","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000174791","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000174791","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000213658","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000213658","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000213658","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000213658","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000213658","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000213658","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000064703","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000064703","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Imfinzi","Durvalumab","CHEMBL3301587","ENSG00000120217","ENSG00000188389","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017
"Tecentriq","Atezolizumab","CHEMBL3707227","ENSG00000120217","ENSG00000188389","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016
"Imfinzi","Durvalumab","CHEMBL3301587","ENSG00000120217","ENSG00000188389","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017
"Tecentriq","Atezolizumab","CHEMBL3707227","ENSG00000120217","ENSG00000188389","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000160255","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000160255","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000160255","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000133124","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000133124","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000133124","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000107643","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000107643","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000107643","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137267","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137267","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137267","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000107643","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000107643","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000107643","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000133124","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000133124","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000133124","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137267","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137267","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137267","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137267","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137267","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137267","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000000938","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000000938","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000000938","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000000938","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000000938","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000000938","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000000938","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000000938","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000000938","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000000938","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000171150","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000171150","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000000938","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000000938","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000000938","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000000938","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000000938","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000000938","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000000938","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000000938","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000000938","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000000938","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000136205","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000136205","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000136205","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000136205","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000136205","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000136205","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000136205","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000136205","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000136205","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000136205","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000074966","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000074966","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000166313","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000166313","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000166313","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000120833","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000120833","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000166313","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000166313","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000166313","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000120833","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000120833","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000198574","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000198574","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000163517","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000163517","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Empliciti","Elotuzumab","CHEMBL1743010","ENSG00000026751","ENSG00000026751","Bristol-Myers Squibb","SLAMF7-directed mAb","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,B",2015
"Empliciti","Elotuzumab","CHEMBL1743010","ENSG00000026751","ENSG00000026751","Bristol-Myers Squibb","SLAMF7-directed mAb","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,B",2015
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000148346","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000064999","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000064999","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000064999","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000147010","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000147010","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000147010","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000135046","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000135046","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000135046","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000184557","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000184557","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000184557","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000184557","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000184557","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000184557","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000184557","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000184557","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000184557","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000184557","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000186834","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000186834","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000186834","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000148053","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000148053","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000148053","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000148053","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000148053","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000148053","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000148053","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000148053","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000148053","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000114805","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000114805","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000114805","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000096968","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000096968","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000096968","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000096968","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000096968","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000096968","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000096968","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000096968","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000096968","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000096968","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000096968","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000096968","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000096968","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000096968","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000096968","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000159352","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000159352","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000159352","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000159352","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000159352","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000159352","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000044574","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000044574","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000044574","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000044574","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000044574","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000044574","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145016","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145016","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145016","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000197122","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000197122","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000197122","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000197122","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000197122","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000102606","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000102606","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000102606","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000197122","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000197122","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000197122","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000197122","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000197122","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000197122","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000197122","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000197122","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000197122","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000197122","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000197122","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000197122","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000197122","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000197122","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000197122","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000080031","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000080031","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000080031","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145335","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145335","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145335","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000080031","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000080031","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000080031","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145335","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145335","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145335","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000071537","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000071537","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000071537","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000071537","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000071537","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000071537","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000100324","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000100324","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000100324","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000100324","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000100324","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000100324","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000185483","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000185483","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000185483","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000185483","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000185483","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000185483","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000185483","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000185483","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000185483","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000182511","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000182511","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000182511","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000182511","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000182511","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000182511","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000182511","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000182511","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000182511","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000182511","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105245","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105245","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105245","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142208","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142208","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142208","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142208","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142208","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142208","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142208","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142208","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142208","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142208","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142208","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142208","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142208","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142208","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142208","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000105976","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105976","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105976","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105976","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000105976","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000105976","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105976","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105976","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105976","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000105976","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000105976","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105976","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105976","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105976","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000105976","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000105976","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105976","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105976","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105976","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000105976","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000105976","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105976","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105976","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105976","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000105976","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000105976","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105976","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105976","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105976","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000105976","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000004478","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000004478","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000004478","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000044115","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000044115","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000044115","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000148082","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000148082","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000148082","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000148082","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000148082","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000187191","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000187191","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000135605","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000135605","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000135605","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000135605","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000135605","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000135605","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170312","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170312","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170312","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000133961","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000133961","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000133961","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170312","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170312","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170312","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170312","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170312","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170312","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170312","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170312","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170312","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000126581","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000126581","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000126581","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000198561","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000198561","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000198561","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000161203","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000161203","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000161203","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113013","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113013","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113013","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000126581","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000126581","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000126581","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113580","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113580","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113580","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113580","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113580","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113580","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000154277","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000154277","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000154277","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113580","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113580","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113580","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000154277","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000154277","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000154277","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000149177","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000149177","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000149177","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000149177","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000149177","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000149177","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000149177","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000149177","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000149177","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000149177","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169375","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169375","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169375","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Imfinzi","Durvalumab","CHEMBL3301587","ENSG00000120217","ENSG00000197646","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017
"Tecentriq","Atezolizumab","CHEMBL3707227","ENSG00000120217","ENSG00000197646","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016
"Imfinzi","Durvalumab","CHEMBL3301587","ENSG00000120217","ENSG00000197646","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017
"Tecentriq","Atezolizumab","CHEMBL3707227","ENSG00000120217","ENSG00000197646","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000111252","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111252","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111252","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111252","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000111252","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000109971","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000109971","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000109971","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000109971","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000109971","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000109971","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111679","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111679","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111679","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111679","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111679","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111679","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111679","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111679","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111679","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000103653","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000103653","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000103653","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111679","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111679","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111679","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141655","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141655","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141655","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000113263","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113263","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113263","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113263","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000113263","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000113263","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113263","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113263","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113263","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000113263","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169047","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169047","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000113263","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113263","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113263","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113263","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000113263","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169047","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169047","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169047","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000113263","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000113263","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000113263","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000113263","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000113263","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000111077","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000111077","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000092208","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000092208","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000115325","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000115325","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000115325","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168003","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168003","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168003","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Praluent","Alirocumab","CHEMBL2109540","ENSG00000169174","ENSG00000130164","Sanofi","PCSK9 inhibitor","Other indication","LDL lowering","low density lipoprotein cholesterol measurement","EFO_0004611","Not serious","P",2015
"Praluent","Alirocumab","CHEMBL2109540","ENSG00000169174","ENSG00000130164","Sanofi","PCSK9 inhibitor","Other indication","LDL lowering","low density lipoprotein cholesterol measurement","EFO_0004611","Not serious","P",2015
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000183020","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000183020","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000183020","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000172757","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000172757","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000172757","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000172757","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000172757","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000172757","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142949","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142949","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142949","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142949","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142949","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142949","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000178568","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000178568","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000178568","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000178568","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000178568","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000178568","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000141738","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000141738","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000178568","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000178568","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000178568","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000109321","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000109321","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000109321","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000141738","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000141738","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000178568","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000178568","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000178568","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000178568","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000178568","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000178568","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000109321","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000109321","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000109321","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000127191","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000127191","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000127191","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000014641","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000014641","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000014641","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000103423","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000103423","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170248","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170248","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170248","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000071051","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000071051","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000071051","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000071051","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000071051","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141480","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141480","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141480","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000198668","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000198668","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000198668","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141480","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141480","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141480","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000198668","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000198668","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000198668","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000167037","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000167037","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101182","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101182","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101182","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Empliciti","Elotuzumab","CHEMBL1743010","ENSG00000026751","ENSG00000183918","Bristol-Myers Squibb","SLAMF7-directed mAb","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,B",2015
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000144749","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000144749","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000144749","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000144749","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000144749","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000144749","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000196154","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000196154","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000196154","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000007264","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000007264","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000196154","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000196154","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000196154","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000196154","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000196154","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000196154","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000010017","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000010017","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000149428","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000149428","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000149428","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000149428","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000149428","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000149428","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000143294","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000143294","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000143294","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000057294","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000057294","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000057294","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000114737","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000114737","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000114737","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000143294","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000143294","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000143294","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000135829","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000101336","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101336","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101336","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101336","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000101336","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000101336","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101336","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101336","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101336","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000101336","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000103266","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000103266","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000103266","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000101336","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101336","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101336","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101336","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000101336","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000103266","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000103266","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000103266","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000134242","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000134242","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000134242","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000101336","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101336","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101336","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101336","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000101336","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137076","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137076","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137076","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000163563","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000163563","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000163563","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000163563","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000152894","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000152894","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000152894","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000152894","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000152894","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000152894","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000152894","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000152894","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000135052","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000135052","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000135052","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000135052","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000135052","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000135052","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105974","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105974","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105974","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105974","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105974","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105974","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000124882","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000124882","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000124882","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000124882","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000124882","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000124882","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000124882","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000124882","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000124882","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000197442","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000197442","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000165025","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000165025","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000165025","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000165025","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000165025","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000127824","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000127824","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000127824","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142627","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142627","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142627","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000165025","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000165025","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000165025","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000165025","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000165025","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142627","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142627","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142627","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000165025","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000165025","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000165025","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000165025","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000165025","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000127824","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000127824","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000127824","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142627","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142627","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142627","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169045","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169045","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169045","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000067560","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000067560","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000134853","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000134853","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000134853","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000067560","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000067560","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000134215","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000134215","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000134853","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000134853","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000134853","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000067560","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000067560","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111640","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111640","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111640","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000134215","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000134215","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000134853","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000134853","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000134853","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000134853","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000134853","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000134853","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000067560","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000067560","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000067560","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000067560","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137486","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137486","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137486","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137486","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137486","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137486","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137486","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137486","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137486","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000107295","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000107295","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000107295","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000107295","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000107295","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000107295","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000123908","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000165731","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000165731","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000165731","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000165731","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000165731","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000165731","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169398","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169398","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169398","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000198753","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000198753","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000149925","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000149925","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000149925","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000165731","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000165731","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000165731","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169398","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169398","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169398","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000198753","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000198753","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000165731","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000165731","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000165731","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169398","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169398","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169398","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000165731","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000165731","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000165731","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000197386","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000197386","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000197386","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000197386","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000110711","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000110711","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000110711","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141736","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141736","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141736","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141736","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141736","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141736","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141736","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141736","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141736","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141736","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141736","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141736","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141736","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141736","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141736","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141736","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141736","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141736","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141736","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141736","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141736","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141736","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141736","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141736","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000089280","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000089280","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000092820","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000092820","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000092820","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000092820","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000092820","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000092820","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000010671","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000010671","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000010671","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000010671","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000140600","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000140600","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000140600","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000010671","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000010671","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000010671","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000010671","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000010671","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000010671","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000140600","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000140600","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000140600","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000141736","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000141736","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000141736","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000097007","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000097007","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000097007","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000097007","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000097007","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000097007","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000174808","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000174808","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000174808","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000097007","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000097007","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000097007","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000167601","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000167601","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000167601","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000174808","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000174808","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000174808","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000097007","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000097007","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000097007","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000167601","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000167601","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000167601","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000102755","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000102755","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000164050","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000164050","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000204389","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000204389","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000204389","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000046653","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000046653","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000046653","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000143398","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000143398","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000143398","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000143398","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000198799","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000198799","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000198799","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105971","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105971","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105971","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000120694","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000120694","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000120694","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000120694","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000120694","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000120694","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000254087","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000254087","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000254087","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000254087","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000254087","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000254087","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000254087","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000254087","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000254087","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000254087","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000254087","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000254087","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000254087","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000254087","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000254087","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000254087","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000254087","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000254087","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000254087","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000254087","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000121058","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000121058","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000087586","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000087586","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000087586","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000087586","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000087586","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000087586","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000101265","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000101265","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000087586","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000087586","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000087586","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000087586","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000087586","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000087586","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000101265","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000101265","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000179295","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000179295","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000179295","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000179295","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000179295","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000167552","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000167552","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000167552","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000179295","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000179295","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000179295","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000179295","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000179295","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000179295","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000179295","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000179295","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000179295","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000179295","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000167552","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000167552","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000167552","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000179295","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000179295","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000179295","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000179295","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000179295","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000179295","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000179295","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000179295","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000179295","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000179295","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000131746","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000131746","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000131746","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000131746","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000131746","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000131746","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000131746","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000131746","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000131746","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000131746","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000131746","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000131746","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000131746","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000131746","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000131746","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000159176","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000159176","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000159176","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000165527","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000165527","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000165527","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000109458","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000109458","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000109458","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000109458","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000109458","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000109458","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000019991","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000019991","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000019991","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000019991","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000019991","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000019991","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000019991","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000019991","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000065361","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000065361","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000065361","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000065361","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000065361","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000065361","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000065361","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000065361","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000065361","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000156973","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000156973","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000065361","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000065361","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000065361","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000156973","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000156973","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000128052","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000128052","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000033327","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000033327","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000033327","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000151834","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000151834","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000151834","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000033327","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000033327","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000033327","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000106070","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000106070","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000106070","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170606","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170606","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170606","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000151834","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000151834","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000151834","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000182004","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000182004","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000117450","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000117450","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000117450","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000185499","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000185499","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000185499","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000117450","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000117450","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000117450","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000185499","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000185499","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000185499","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000117450","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000117450","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000117450","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000185499","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000185499","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000185499","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000185499","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000185499","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000185499","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000185499","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000185499","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000185499","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000189043","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000189043","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000189043","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000163697","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000163697","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000163697","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000189043","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000189043","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000189043","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000189043","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000189043","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000189043","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000082516","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000082516","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Imfinzi","Durvalumab","CHEMBL3301587","ENSG00000120217","ENSG00000121594","AstraZeneca","PDL1-blocking antibody","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2017
"Tecentriq","Atezolizumab","CHEMBL3707227","ENSG00000120217","ENSG00000121594","Genentech","PDL1 inhibitor","Oncology","Urothelial carcinoma","urothelial carcinoma","EFO_0008528","Serious","P,B,A",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000153707","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000153707","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000153707","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000153707","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000153707","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000153707","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000067182","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000067182","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000067182","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000067182","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000067182","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000067182","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000153707","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000153707","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000153707","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000153707","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000153707","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000153707","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000153707","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000153707","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000153707","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000132155","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000132155","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000132155","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000132155","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000132155","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000132155","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000132155","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000132155","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000132155","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000132155","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000177885","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000177885","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000177885","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000177885","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000177885","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000132155","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000132155","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000132155","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000132155","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000132155","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000132155","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000132155","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000132155","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000132155","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000132155","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000177885","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000177885","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000177885","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000177885","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000177885","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000132155","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000132155","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000132155","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000132155","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000132155","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000177885","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000177885","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000177885","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000177885","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000177885","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000132155","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000132155","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000132155","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000132155","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000132155","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000169057","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000169057","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000169057","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000169057","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000182866","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000182866","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000182866","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000182866","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000188191","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000188191","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000188191","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000144746","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000144746","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000182866","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000182866","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000182866","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000182866","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000101213","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101213","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101213","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101213","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000101213","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000099942","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000099942","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000099942","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000101213","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101213","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101213","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101213","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000101213","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000099942","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000099942","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000099942","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000101213","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101213","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101213","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101213","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000101213","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000101213","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101213","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101213","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101213","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000101213","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000133703","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000133703","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000133703","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000133703","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000133703","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000133703","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000133703","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000133703","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000133703","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000133703","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000164615","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000164615","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000164615","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000133703","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000133703","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000133703","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000133703","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000133703","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000133703","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000133703","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000133703","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105401","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105401","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105401","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000166598","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000166598","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000166598","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000166598","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000166598","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000166598","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000137936","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000137936","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000173801","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000173801","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000173801","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000173801","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000173801","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000173801","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168610","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168610","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168610","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168610","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168610","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168610","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168610","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168610","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168610","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168610","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168610","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168610","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000168610","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000168610","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000168610","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000095370","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000095370","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000095370","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000095370","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000095370","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000141510","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000141510","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000141510","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000141510","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000141510","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000141510","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000011485","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000011485","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000011485","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000123384","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000123384","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000123384","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000123384","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000123384","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000123384","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000172062","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000172062","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000172062","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000172062","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000172062","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000172062","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000172062","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000172062","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000172062","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000172062","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000172062","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000172062","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000172062","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000172062","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000172062","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000172062","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000140538","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000140538","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000149269","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000149269","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000149269","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000104814","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000104814","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000104814","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000140009","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000140009","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000140009","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000140538","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000140538","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000144724","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000144724","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000144724","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000144724","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000144724","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000149269","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000149269","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000149269","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000140009","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000140009","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000140009","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000140538","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000140538","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000101134","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000101134","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000101134","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000178078","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000178078","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000178078","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000132970","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000132970","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000132970","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000132970","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000132970","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000132970","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000178078","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000178078","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000178078","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141968","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141968","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141968","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141968","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141968","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141968","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000145715","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145715","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145715","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145715","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000145715","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170581","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170581","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170581","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170581","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170581","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170581","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000141968","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000141968","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000141968","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000145715","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145715","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145715","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145715","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000145715","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000162591","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000162591","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000162591","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170581","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170581","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170581","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105613","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105613","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105613","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000253729","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000253729","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000253729","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000253729","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000253729","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000253729","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000124181","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000124181","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000124181","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000124181","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000124181","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000144554","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000144554","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000144554","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000145675","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145675","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145675","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145675","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000145675","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000124181","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000124181","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000124181","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000124181","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000124181","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000144554","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000144554","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000144554","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000145675","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145675","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145675","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145675","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000145675","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000124181","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000124181","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000124181","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000124181","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000124181","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000144554","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000144554","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000144554","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000145675","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145675","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145675","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145675","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000145675","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000145675","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145675","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145675","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145675","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000145675","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000144554","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000144554","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000144554","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000145675","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000145675","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000145675","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000145675","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000145675","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000198399","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000198399","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000198399","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000159228","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000159228","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000159228","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000127947","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000127947","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000127947","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000127947","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000127947","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000127947","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000127947","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000127947","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000127947","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000127947","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000130402","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000130402","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000130402","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000178188","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000178188","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000178188","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000178188","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000178188","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000138798","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000138798","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000138798","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000116285","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000116285","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000116285","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000125170","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000125170","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000125170","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000138798","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000138798","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000138798","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000197102","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000197102","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000197102","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000078061","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000078061","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000078061","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000078061","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000078061","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000078061","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000078061","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000078061","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000240972","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000240972","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000240972","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000078061","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000078061","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000078061","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000078061","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000204305","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000204305","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000204305","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000204305","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000204305","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000204305","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000184144","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000184144","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000184144","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000131558","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000131558","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000131558","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000184144","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000184144","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000184144","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000142192","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142192","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142192","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142192","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000142192","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Lumakras","Sotorasib","CHEMBL4535757","ENSG00000133703","ENSG00000142192","Amgen","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000142192","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000142192","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000142192","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Krazati","Adagrasib","CHEMBL4594350","ENSG00000133703","ENSG00000142192","Mirati","KRAS-G12C inhibitor","Oncology","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,B,A,F",2022
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000050748","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000050748","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000050748","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000174437","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000174437","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000174437","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000050748","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000050748","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000050748","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000094631","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000094631","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000094631","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000174437","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000174437","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000174437","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000094631","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000094631","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000094631","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000174437","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000174437","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000174437","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000160691","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000160691","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000160691","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000160691","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000160691","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000160691","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000160691","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000160691","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000160691","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000160691","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000160691","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000160691","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000160691","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000160691","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000160691","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000099250","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Beovu","Brolucizumab","CHEMBL3707357","ENSG00000112715","ENSG00000099250","Novartis","VEGF inhibitor","Other indication","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Not concordant","S",2019
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000158402","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000158402","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000158402","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000158402","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000158402","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000158402","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000170677","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000170677","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000170677","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000170677","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000170677","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000158402","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000158402","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000158402","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000107290","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000107290","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000107290","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000107290","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000107290","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000107290","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000100485","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000100485","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000100485","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000115904","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000115904","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000115904","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000100485","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000100485","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000100485","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000115904","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000115904","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000115904","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000167193","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000167193","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000167193","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000167193","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000167193","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000115904","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000115904","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000115904","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000205571","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000205571","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000205571","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000205571","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000205571","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000205571","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000205571","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000205571","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000205571","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000205571","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000205571","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000205571","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000205571","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000205571","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000165458","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000165458","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000154127","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000154127","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000154127","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000141499","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000141499","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000177666","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000177666","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000177666","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000023734","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000023734","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137193","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137193","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137193","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000176105","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000176105","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000176105","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000176105","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000176105","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000136810","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000136810","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000136810","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137193","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137193","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137193","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000164924","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000164924","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000164924","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000176105","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000176105","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000176105","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000176105","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000176105","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000176105","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000176105","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000176105","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000176105","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000176105","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000070159","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000070159","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000070159","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000070159","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000130558","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000130558","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000130558","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000069869","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000069869","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000069869","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000154229","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000154229","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000154229","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000069869","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000069869","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000069869","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000154229","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000154229","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000154229","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000154229","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000154229","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000154229","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000088930","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000088930","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000088930","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146674","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146674","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146674","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146674","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146674","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146674","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000146674","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000146674","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000146674","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000089685","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000132639","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000132639","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000132639","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000102010","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000102010","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000102010","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Evrysdi","Risdiplam","CHEMBL4297528","ENSG00000205571","ENSG00000198513","Roche/Genentech","SMN2 splicing modifier","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2020
"Spinraza","Nusinersen","CHEMBL3301572","ENSG00000205571","ENSG00000198513","Biogen/Ionis Pharmaceuticals","ASO designed to target SMN2 pre-mRNA","Other indication","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Serious","P,O,F",2016
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000105647","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105647","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105647","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105647","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000105647","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000105647","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105647","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105647","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105647","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000105647","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000105647","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000105647","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000105647","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000105647","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000105647","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000138698","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000138698","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000138698","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000092758","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000092758","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000092758","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169139","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169139","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169139","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000138698","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000138698","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000138698","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000148180","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000148180","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000148180","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169139","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169139","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169139","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000169139","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000169139","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000169139","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000080824","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000080824","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000080824","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000080824","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000080824","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000080824","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000080824","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000080824","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000080824","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000085733","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000085733","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000085733","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000175793","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000175793","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000175793","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000080824","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000080824","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000080824","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000175793","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000175793","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000175793","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000157168","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000157168","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000157168","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000157168","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000157168","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000157168","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137462","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137462","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137462","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000157168","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000157168","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000157168","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000157168","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000157168","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000157168","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111669","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111669","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111669","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000137462","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000137462","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000137462","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000157168","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000157168","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000157168","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000173020","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000173020","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000173020","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000111669","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000111669","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000111669","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Praluent","Alirocumab","CHEMBL2109540","ENSG00000169174","ENSG00000169174","Sanofi","PCSK9 inhibitor","Other indication","LDL lowering","low density lipoprotein cholesterol measurement","EFO_0004611","Not serious","P",2015
"Praluent","Alirocumab","CHEMBL2109540","ENSG00000169174","ENSG00000169174","Sanofi","PCSK9 inhibitor","Other indication","LDL lowering","low density lipoprotein cholesterol measurement","EFO_0004611","Not serious","P",2015
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000067225","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000067225","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000067225","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000067225","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000067225","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000067225","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000067225","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000067225","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000067225","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000067225","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000123908","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000123908","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000123908","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000123908","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000123908","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000123908","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000250722","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000250722","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000250722","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Xpovio","Selinexor","CHEMBL3545185","ENSG00000082898","ENSG00000162692","Karyopharm Therapeutics","XPO1 inhibitor","Oncology","Multiple myeloma","multiple myeloma","EFO_0001378","Serious","P,O,A,F",2019
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000100351","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000100351","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000100351","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000085063","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000085063","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000085063","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000100351","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000100351","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000100351","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000107263","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000107263","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000107263","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000107263","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000107263","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000107263","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000196396","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000196396","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000196396","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000196396","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000196396","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000039068","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000039068","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000039068","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000039068","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000039068","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000039068","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000039068","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000039068","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000039068","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000136235","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000136235","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000136235","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000160293","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000160293","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000136235","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000136235","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000136235","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Tepmetko","Tepotinib","CHEMBL3402762","ENSG00000105976","ENSG00000160293","EMD Serono","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,A",2021
"Tabrecta","Capmatinib","CHEMBL3188267","ENSG00000105976","ENSG00000160293","Novartis","MET kinase inhibitor","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A",2020
"Tagrisso","Osimertinib","CHEMBL3353410","ENSG00000146648","ENSG00000133056","AstraZeneca","EGFR inhibitor","Oncology","NSCLC with EGFRT790M mutations","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2015
"Portrazza","Necitumumab","CHEMBL1743047","ENSG00000146648","ENSG00000133056","Eli Lilly","EGFR antagonist","Oncology","NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","S,O,F",2015
"Exkivity","Mobocertinib","CHEMBL4650319","ENSG00000146648","ENSG00000133056","Takeda","EGFR kinase inhibitor","Oncology","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Serious","P,O,B,A,F",2021
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000115263","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000115263","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Ubrelvy","Ubrogepant","CHEMBL2364638","ENSG00000064989","ENSG00000148926","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019
"Nurtec ODT","Rimegepant","CHEMBL2178422","ENSG00000064989","ENSG00000148926","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020
"Aimovig","Erenumab","CHEMBL3833329","ENSG00000064989","ENSG00000148926","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018
"Qulipta","Atogepant","CHEMBL3991065","ENSG00000064989","ENSG00000148926","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021
"Bevyxxa","Betrixaban","CHEMBL512351","ENSG00000126218","ENSG00000117601","Portola Pharmaceuticals","FXa inhibitor","Other indication","Prophylaxis of venous thromboembolism","venous thromboembolism","EFO_0004286","Serious","P,F",2017
"Bevyxxa","Betrixaban","CHEMBL512351","ENSG00000126218","ENSG00000117601","Portola Pharmaceuticals","FXa inhibitor","Other indication","Prophylaxis of venous thromboembolism","venous thromboembolism","EFO_0004286","Serious","P,F",2017
"Bevyxxa","Betrixaban","CHEMBL512351","ENSG00000126218","ENSG00000117601","Portola Pharmaceuticals","FXa inhibitor","Other indication","Prophylaxis of venous thromboembolism","venous thromboembolism","EFO_0004286","Serious","P,F",2017
"Adlyxin","Lixisenatide","CHEMBL2108336","ENSG00000112164","ENSG00000254997","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000103266","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000103266","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000127329","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000005893","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000170775","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Klisyri","Tirbanibulin","CHEMBL571546","ENSG00000197122","ENSG00000039068","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020
"Klisyri","Tirbanibulin","CHEMBL571546","ENSG00000197122","ENSG00000241794","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020
"Ingrezza","Valbenazine","CHEMBL2364639","ENSG00000165646","ENSG00000139514","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017
"Ingrezza","Valbenazine","CHEMBL2364639","ENSG00000165646","ENSG00000139514","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000114062","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Ubrelvy","Ubrogepant","CHEMBL2364638","ENSG00000064989","ENSG00000110680","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019
"Nurtec ODT","Rimegepant","CHEMBL2178422","ENSG00000064989","ENSG00000110680","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020
"Aimovig","Erenumab","CHEMBL3833329","ENSG00000064989","ENSG00000110680","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018
"Qulipta","Atogepant","CHEMBL3991065","ENSG00000064989","ENSG00000110680","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021
"Ubrelvy","Ubrogepant","CHEMBL2364638","ENSG00000064989","ENSG00000110680","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019
"Nurtec ODT","Rimegepant","CHEMBL2178422","ENSG00000064989","ENSG00000110680","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020
"Aimovig","Erenumab","CHEMBL3833329","ENSG00000064989","ENSG00000110680","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018
"Qulipta","Atogepant","CHEMBL3991065","ENSG00000064989","ENSG00000110680","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021
"Ubrelvy","Ubrogepant","CHEMBL2364638","ENSG00000064989","ENSG00000110680","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019
"Nurtec ODT","Rimegepant","CHEMBL2178422","ENSG00000064989","ENSG00000110680","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020
"Aimovig","Erenumab","CHEMBL3833329","ENSG00000064989","ENSG00000110680","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018
"Qulipta","Atogepant","CHEMBL3991065","ENSG00000064989","ENSG00000110680","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000068078","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000068078","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Daurismo","Glasdegib","CHEMBL2043437","ENSG00000128602","ENSG00000185920","Pfizer","Hedgehog pathway inhibitor","Oncology","AML","acute myeloid leukemia","EFO_0000222","Serious","P,O",2018
"Daurismo","Glasdegib","CHEMBL2043437","ENSG00000128602","ENSG00000185920","Pfizer","Hedgehog pathway inhibitor","Oncology","AML","acute myeloid leukemia","EFO_0000222","Serious","P,O",2018
"Daurismo","Glasdegib","CHEMBL2043437","ENSG00000128602","ENSG00000185920","Pfizer","Hedgehog pathway inhibitor","Oncology","AML","acute myeloid leukemia","EFO_0000222","Serious","P,O",2018
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000141480","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000135018","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Adlyxin","Lixisenatide","CHEMBL2108336","ENSG00000112164","ENSG00000221880","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000172156","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000172156","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000120937","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000120937","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Scemblix","Asciminib","CHEMBL4208229","ENSG00000097007","ENSG00000122025","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021
"Scemblix","Asciminib","CHEMBL4208229","ENSG00000097007","ENSG00000122025","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021
"Scemblix","Asciminib","CHEMBL4208229","ENSG00000097007","ENSG00000122025","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000141433","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000141433","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000109501","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000109501","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000189221","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000116729","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000149177","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Adlyxin","Lixisenatide","CHEMBL2108336","ENSG00000112164","ENSG00000272804","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016
"Striverdi Respimat","Olodaterol","CHEMBL605846","ENSG00000169252","ENSG00000106462","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014
"Striverdi Respimat","Olodaterol","CHEMBL605846","ENSG00000169252","ENSG00000197971","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000138794","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000126895","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000126895","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Klisyri","Tirbanibulin","CHEMBL571546","ENSG00000197122","ENSG00000146648","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000102962","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000102962","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000140443","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000140443","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000140443","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000072062","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000261371","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000118702","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000118702","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000127947","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Klisyri","Tirbanibulin","CHEMBL571546","ENSG00000197122","ENSG00000168036","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020
"Tzield","Teplizumab","CHEMBL1743078","ENSG00000198851","ENSG00000115085","Provention Bio","CD3-targeted antibody","Other indication","Delay onset of type 1 diabetes","type 1 diabetes mellitus","MONDO_0005147","Not concordant","P,B",2022
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000131096","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000131096","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Ubrelvy","Ubrogepant","CHEMBL2364638","ENSG00000064989","ENSG00000132329","Allergan","CGRP receptor antagonist","Other indication","Migraine with or without aura","migraine disorder","MONDO_0005277","Not serious","S",2019
"Nurtec ODT","Rimegepant","CHEMBL2178422","ENSG00000064989","ENSG00000132329","Biohaven","CGRP receptor antagonist","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2020
"Aimovig","Erenumab","CHEMBL3833329","ENSG00000064989","ENSG00000132329","Amgen/Novartis","CGRP receptor antibody","Other indication","Migraine","migraine disorder","MONDO_0005277","Not serious","S",2018
"Qulipta","Atogepant","CHEMBL3991065","ENSG00000064989","ENSG00000132329","AbbVie","CGRP receptor antagonist","Other indication","Episodic migraine","migraine disorder","MONDO_0005277","Not serious","S",2021
"Bevyxxa","Betrixaban","CHEMBL512351","ENSG00000126218","ENSG00000140093","Portola Pharmaceuticals","FXa inhibitor","Other indication","Prophylaxis of venous thromboembolism","venous thromboembolism","EFO_0004286","Serious","P,F",2017
"Yupelri","Revefenacin","CHEMBL3833319","ENSG00000133019","ENSG00000184984","Theravance Biopharma/Mylan","Long-acting muscarinic receptor antagonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2018
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000170425","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000170425","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Striverdi Respimat","Olodaterol","CHEMBL605846","ENSG00000169252","ENSG00000113369","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000185897","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000169047","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000169047","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000169047","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000169047","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000169047","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000169047","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Adlyxin","Lixisenatide","CHEMBL2108336","ENSG00000112164","ENSG00000188581","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016
"Tzield","Teplizumab","CHEMBL1743078","ENSG00000198851","ENSG00000149451","Provention Bio","CD3-targeted antibody","Other indication","Delay onset of type 1 diabetes","type 1 diabetes mellitus","MONDO_0005147","Not concordant","P,B",2022
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000174775","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Klisyri","Tirbanibulin","CHEMBL571546","ENSG00000197122","ENSG00000168610","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000135439","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Adlyxin","Lixisenatide","CHEMBL2108336","ENSG00000112164","ENSG00000187766","Sanofi","GLP1 receptor agonist","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2016
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000081237","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000081237","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000081237","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000081237","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000144724","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000197635","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000197635","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000197635","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000197635","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000197635","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000197635","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000171105","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Ingrezza","Valbenazine","CHEMBL2364639","ENSG00000165646","ENSG00000180871","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017
"Ingrezza","Valbenazine","CHEMBL2364639","ENSG00000165646","ENSG00000180871","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000163050","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Tzield","Teplizumab","CHEMBL1743078","ENSG00000198851","ENSG00000176171","Provention Bio","CD3-targeted antibody","Other indication","Delay onset of type 1 diabetes","type 1 diabetes mellitus","MONDO_0005147","Not concordant","P,B",2022
"Klisyri","Tirbanibulin","CHEMBL571546","ENSG00000197122","ENSG00000197122","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020
"Klisyri","Tirbanibulin","CHEMBL571546","ENSG00000197122","ENSG00000197122","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000138755","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000138755","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000179218","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000179218","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000179218","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000254647","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000185950","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000185950","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000185950","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000124181","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000124181","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000153233","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000153233","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Ponvory","Ponesimod","CHEMBL1096146","ENSG00000170989","ENSG00000110848","J&J","S1P receptor modulator","Other indication","Relapsing multiple sclerosis","multiple sclerosis","MONDO_0005301","Serious","S",2021
"Zeposia","Ozanimod","CHEMBL3707247","ENSG00000170989","ENSG00000110848","Celgene/Bristol Myers Squibb","S1P receptor modulator","Other indication","Multiple sclerosis","multiple sclerosis","MONDO_0005301","Serious","S",2020
"Ponvory","Ponesimod","CHEMBL1096146","ENSG00000170989","ENSG00000110848","J&J","S1P receptor modulator","Other indication","Relapsing multiple sclerosis","multiple sclerosis","MONDO_0005301","Serious","S",2021
"Zeposia","Ozanimod","CHEMBL3707247","ENSG00000170989","ENSG00000110848","Celgene/Bristol Myers Squibb","S1P receptor modulator","Other indication","Multiple sclerosis","multiple sclerosis","MONDO_0005301","Serious","S",2020
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000178188","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000178188","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000178188","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000160014","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000106070","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000106070","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000106070","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Idhifa","Enasidenib mesylate","CHEMBL3989931","ENSG00000182054","ENSG00000182054","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017
"Idhifa","Enasidenib mesylate","CHEMBL3989931","ENSG00000182054","ENSG00000182054","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017
"Idhifa","Enasidenib mesylate","CHEMBL3989931","ENSG00000182054","ENSG00000182054","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017
"Idhifa","Enasidenib mesylate","CHEMBL3989931","ENSG00000182054","ENSG00000182054","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017
"Idhifa","Enasidenib mesylate","CHEMBL3989931","ENSG00000182054","ENSG00000182054","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017
"Idhifa","Enasidenib mesylate","CHEMBL3989931","ENSG00000182054","ENSG00000182054","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017
"Idhifa","Enasidenib mesylate","CHEMBL3989931","ENSG00000182054","ENSG00000182054","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017
"Idhifa","Enasidenib mesylate","CHEMBL3989931","ENSG00000182054","ENSG00000182054","Celgene/Agios","IDH2 inhibitor","Oncology","IDH2-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","P,O,F",2017
"Scemblix","Asciminib","CHEMBL4208229","ENSG00000097007","ENSG00000197122","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000146469","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000146469","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Scemblix","Asciminib","CHEMBL4208229","ENSG00000097007","ENSG00000157404","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021
"Scemblix","Asciminib","CHEMBL4208229","ENSG00000097007","ENSG00000157404","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021
"Scemblix","Asciminib","CHEMBL4208229","ENSG00000097007","ENSG00000157404","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000097033","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000149295","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000149295","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000149295","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Striverdi Respimat","Olodaterol","CHEMBL605846","ENSG00000169252","ENSG00000163485","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014
"Striverdi Respimat","Olodaterol","CHEMBL605846","ENSG00000169252","ENSG00000163485","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000094796","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000271503","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000271503","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000075624","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000075624","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000128271","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000128271","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000107562","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000107562","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000099377","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000163513","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000163513","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Klisyri","Tirbanibulin","CHEMBL571546","ENSG00000197122","ENSG00000174775","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020
"Klisyri","Tirbanibulin","CHEMBL571546","ENSG00000197122","ENSG00000174775","Athenex","Microtubule inhibitor","Other indication","Actinic keratosis","actinic keratosis","EFO_0002496","Not serious","S",2020
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000179295","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000179295","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000179295","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000160691","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tzield","Teplizumab","CHEMBL1743078","ENSG00000198851","ENSG00000165025","Provention Bio","CD3-targeted antibody","Other indication","Delay onset of type 1 diabetes","type 1 diabetes mellitus","MONDO_0005147","Not concordant","P,B",2022
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000011465","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000169248","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000169248","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000169248","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000169248","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000138413","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000138413","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000138413","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000138413","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000138413","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000138413","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000138413","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Rezlidhia","Olutasidenib","CHEMBL4297610","ENSG00000138413","ENSG00000138413","Rigel/Forma","IDH1 inhibitor","Oncology","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Serious","S,O",2022
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000163485","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000163485","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000145675","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Scemblix","Asciminib","CHEMBL4208229","ENSG00000097007","ENSG00000149311","Novartis","ABL/BCR-ABL1  kinase inhibitor","Oncology","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Serious","P,O,B,A,F",2021
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000169245","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000169245","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000017427","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000070748","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000188822","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000148180","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Ongentys","Opicapone","CHEMBL1089318","ENSG00000093010","ENSG00000148180","Neurocrine","COMT inhibitor","Other indication","Parkinson disease","parkinson disease","MONDO_0005180","Serious","S",2020
"Lupkynis","Voclosporin","CHEMBL2218919","ENSG00000138814","ENSG00000101096","Aurinia","Calcineurin inhibitor","Other indication","Lupus nephritis","lupus nephritis","EFO_0005761","Serious","P,F",2021
"Striverdi Respimat","Olodaterol","CHEMBL605846","ENSG00000169252","ENSG00000197122","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000196396","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000196396","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Daurismo","Glasdegib","CHEMBL2043437","ENSG00000128602","ENSG00000186469","Pfizer","Hedgehog pathway inhibitor","Oncology","AML","acute myeloid leukemia","EFO_0000222","Serious","P,O",2018
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000152894","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000118432","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Nourianz","Istradefylline","CHEMBL431770","ENSG00000128271","ENSG00000118432","Kyowa Kirin","Adenosine receptor antagonist","Other indication","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Serious","S",2019
"Lupkynis","Voclosporin","CHEMBL2218919","ENSG00000138814","ENSG00000002834","Aurinia","Calcineurin inhibitor","Other indication","Lupus nephritis","lupus nephritis","EFO_0005761","Serious","P,F",2021
"Vyvgart","Efgartigimod alfa","CHEMBL4297551","ENSG00000104870","ENSG00000163631","Argenx","FcRn-binding Fc fragment","Other indication","Myasthenia gravis","Myasthenia gravis","EFO_0004991","Serious","S,O,F",2021
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000159224","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000159224","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000159224","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000159224","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000122585","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000122585","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000102466","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Xadago","Safinamide","CHEMBL396778","ENSG00000069535","ENSG00000102466","US WorldMeds","MAO-B inhibitor","Other indication","Parkinson disease","Parkinson disease","MONDO_0005180","Serious","S",2017
"Striverdi Respimat","Olodaterol","CHEMBL605846","ENSG00000169252","ENSG00000141480","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000006128","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Nesina","Alogliptin","CHEMBL376359","ENSG00000197635","ENSG00000006128","Takeda","DPP4 inhibitor","Other indication","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Not concordant","S",2013
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000027644","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000197594","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000197594","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000197594","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000197594","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Tresiba","Insulin degludec","CHEMBL2107869","ENSG00000171105","ENSG00000197594","Novo Nordisk","Long-acting insulin","Other indication","Diabetes","diabetes mellitus","EFO_0000400","Not concordant","S",2015
"Ingrezza","Valbenazine","CHEMBL2364639","ENSG00000165646","ENSG00000173250","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017
"Ingrezza","Valbenazine","CHEMBL2364639","ENSG00000165646","ENSG00000173250","Neurocrine Biosciences","VMAT2 inhibitor","Other indication","Tardive dyskinesia","movement disorder","EFO_0004280","Not concordant","P,B,F",2017
"Striverdi Respimat","Olodaterol","CHEMBL605846","ENSG00000169252","ENSG00000169252","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014
"Striverdi Respimat","Olodaterol","CHEMBL605846","ENSG00000169252","ENSG00000169252","Boehringer Ingelheim","Long-acting beta2-adrenoceptor agonist","Other indication","COPD","chronic obstructive pulmonary disease","EFO_0000341","Serious","S",2014
"Tepezza","Teprotumumab","CHEMBL1743079","ENSG00000140443","ENSG00000150093","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020
"Briumvi","Ublituximab","CHEMBL2108354","ENSG00000156738","ENSG00000144648","TG Therapeutics","CD20-targeted mAb","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2022
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000000938","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000000938","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000138207","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000138207","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000118271","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000118271","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000118271","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000118271","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000118271","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000118271","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000118271","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Kynamro","Mipomersen","CHEMBL2219536","ENSG00000084674","ENSG00000130164","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013
"Kynamro","Mipomersen","CHEMBL2219536","ENSG00000084674","ENSG00000130164","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013
"Kynamro","Mipomersen","CHEMBL2219536","ENSG00000084674","ENSG00000130164","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013
"Kynamro","Mipomersen","CHEMBL2219536","ENSG00000084674","ENSG00000130164","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000166595","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000087088","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000087088","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000197153","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000159459","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Imjudo","Tremelimumab","CHEMBL2108658","ENSG00000163599","ENSG00000114013","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000134569","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000015475","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000015475","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000110092","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000198625","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000198625","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000107338","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000100030","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000100030","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000100030","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Keytruda","Pembrolizumab","CHEMBL3137343","ENSG00000188389","ENSG00000121594","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014
"Opdivo","Nivolumab","CHEMBL2108738","ENSG00000188389","ENSG00000121594","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000174775","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000132155","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000132155","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Tymlos","Abaloparatide","CHEMBL3301581","ENSG00000160801","ENSG00000152266","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000171552","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000171552","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000142192","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000142192","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000142192","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000204305","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141510","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141510","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141510","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141510","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141510","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141510","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141510","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141510","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000142168","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Imjudo","Tremelimumab","CHEMBL2108658","ENSG00000163599","ENSG00000121594","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000070061","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000133703","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000169136","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Evkeeza","Evinacumab","CHEMBL3545191","ENSG00000132855","ENSG00000175445","Regeneron","ANGPTL3-targeted mAb","Other indication","HoFH","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","P,O,B",2021
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000165637","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000254087","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000254087","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000187555","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000113575","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Qelbree","Viloxazine","CHEMBL306700","ENSG00000103546","ENSG00000100151","Supernus","SNRI","Other indication","ADHD","attention deficit hyperactivity disorder","EFO_0003888","Not serious","S",2021
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000198959","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000198959","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000142515","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Korsuva","Difelikefalin","CHEMBL3989915","ENSG00000082556","ENSG00000198932","Cara Therapeutics","kappa-Opioid receptor agonist","Other indication","Pruritus associated with CKD","chronic kidney disease","EFO_0003884","Serious","P,B",2021
"Tecfidera","Dimethyl fumarate","CHEMBL2107333","ENSG00000079999","ENSG00000090339","Biogen Idec","MOA unknown; activates NRF2 pathway","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2013
"Briumvi","Ublituximab","CHEMBL2108354","ENSG00000156738","ENSG00000168685","TG Therapeutics","CD20-targeted mAb","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2022
"Tecfidera","Dimethyl fumarate","CHEMBL2107333","ENSG00000079999","ENSG00000116044","Biogen Idec","MOA unknown; activates NRF2 pathway","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2013
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000170035","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000169032","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000169032","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Gazyva","Obinutuzumab","CHEMBL1743048","ENSG00000156738","ENSG00000157613","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141682","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141682","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000141682","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Tymlos","Abaloparatide","CHEMBL3301581","ENSG00000160801","ENSG00000198668","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000169083","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000169083","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000101336","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000101336","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Briumvi","Ublituximab","CHEMBL2108354","ENSG00000156738","ENSG00000156738","TG Therapeutics","CD20-targeted mAb","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2022
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000162337","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000162337","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000162337","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000162337","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000162337","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000162337","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000162337","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Tymlos","Abaloparatide","CHEMBL3301581","ENSG00000160801","ENSG00000087494","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017
"Tymlos","Abaloparatide","CHEMBL3301581","ENSG00000160801","ENSG00000087494","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000132437","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000171791","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000171791","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000171791","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000171791","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000171791","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000123358","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000123358","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000116288","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000171132","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Korsuva","Difelikefalin","CHEMBL3989915","ENSG00000082556","ENSG00000134817","Cara Therapeutics","kappa-Opioid receptor agonist","Other indication","Pruritus associated with CKD","chronic kidney disease","EFO_0003884","Serious","P,B",2021
"Keytruda","Pembrolizumab","CHEMBL3137343","ENSG00000188389","ENSG00000120217","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014
"Opdivo","Nivolumab","CHEMBL2108738","ENSG00000188389","ENSG00000120217","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014
"Keytruda","Pembrolizumab","CHEMBL3137343","ENSG00000188389","ENSG00000120217","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014
"Opdivo","Nivolumab","CHEMBL2108738","ENSG00000188389","ENSG00000120217","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014
"Tymlos","Abaloparatide","CHEMBL3301581","ENSG00000160801","ENSG00000168036","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017
"Tymlos","Abaloparatide","CHEMBL3301581","ENSG00000160801","ENSG00000168036","Radius Health","Parathyroid hormone-related protein","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2017
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000100290","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000140575","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000170027","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000153094","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000153094","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000119614","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Gazyva","Obinutuzumab","CHEMBL1743048","ENSG00000156738","ENSG00000156738","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013
"Gazyva","Obinutuzumab","CHEMBL1743048","ENSG00000156738","ENSG00000156738","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013
"Gazyva","Obinutuzumab","CHEMBL1743048","ENSG00000156738","ENSG00000156738","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013
"Keytruda","Pembrolizumab","CHEMBL3137343","ENSG00000188389","ENSG00000179295","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014
"Opdivo","Nivolumab","CHEMBL2108738","ENSG00000188389","ENSG00000179295","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000029363","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000029363","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000096384","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Imjudo","Tremelimumab","CHEMBL2108658","ENSG00000163599","ENSG00000145675","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022
"Imjudo","Tremelimumab","CHEMBL2108658","ENSG00000163599","ENSG00000145675","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022
"Imjudo","Tremelimumab","CHEMBL2108658","ENSG00000163599","ENSG00000145675","AstraZeneca","CTLA4-targeted mAb","Oncology","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Serious","S,O",2022
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000128609","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000184557","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Korsuva","Difelikefalin","CHEMBL3989915","ENSG00000082556","ENSG00000105374","Cara Therapeutics","kappa-Opioid receptor agonist","Other indication","Pruritus associated with CKD","chronic kidney disease","EFO_0003884","Serious","P,B",2021
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000044574","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Zynlonta","Loncastuximab tesirine","CHEMBL4297778","ENSG00000177455","ENSG00000211899","ADC Therapeutics","CD19-targeted ADC","Oncology","B-cell lymphoma","B-cell non-Hodgkins lymphoma","EFO_1001938","Serious","P,O,A",2021
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000213281","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000105327","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Kynamro","Mipomersen","CHEMBL2219536","ENSG00000084674","ENSG00000138823","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013
"Kynamro","Mipomersen","CHEMBL2219536","ENSG00000084674","ENSG00000138823","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013
"Kynamro","Mipomersen","CHEMBL2219536","ENSG00000084674","ENSG00000138823","Genzyme","Oligonucleotide inhibitor of apolipoprotein B100 synthesis","Other indication","Homozygous familial hypercholesterolaemia","homozygous familial hypercholesterolemia","MONDO_0018328","Serious","S,O",2013
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000157764","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000157764","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000187678","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000030110","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Venclexta","Venetoclax","CHEMBL3137309","ENSG00000171791","ENSG00000030110","AbbVie","BCL-2 inhibitor","Oncology","Chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B,A",2016
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000132016","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000139372","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Keytruda","Pembrolizumab","CHEMBL3137343","ENSG00000188389","ENSG00000197646","Merck & Co.","PD1-specific antibody","Oncology","Metastatic melanoma *and others (2021 approval)","metastatic melanoma","EFO_0002617","Serious","P,O,B,A",2014
"Opdivo","Nivolumab","CHEMBL2108738","ENSG00000188389","ENSG00000197646","Bristol-Myers Squibb","PD1 inhibitor","Oncology","Unresectable or metastatic melanoma","metastatic melanoma","EFO_0002617","Serious","P,O,B,A,F",2014
"Gazyva","Obinutuzumab","CHEMBL1743048","ENSG00000156738","ENSG00000168685","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013
"Gazyva","Obinutuzumab","CHEMBL1743048","ENSG00000156738","ENSG00000168685","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013
"Gazyva","Obinutuzumab","CHEMBL1743048","ENSG00000156738","ENSG00000168685","Genentech","Humanized CD20-specific monoclonal antibody","Oncology","Previously untreated chronic lymphocytic leukaemia","chronic lymphocytic leukemia","EFO_0000095","Serious","P,O,B",2013
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000078061","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000078061","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000128272","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000128272","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Tepezza","Teprotumumab","CHEMBL1743079","ENSG00000140443","ENSG00000140443","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020
"Tepezza","Teprotumumab","CHEMBL1743079","ENSG00000140443","ENSG00000140443","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020
"Tepezza","Teprotumumab","CHEMBL1743079","ENSG00000140443","ENSG00000171105","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000126934","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Tafinlar","Dabrafenib","CHEMBL2028663","ENSG00000157764","ENSG00000126934","GSK","Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases","Oncology","Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test","metastatic melanoma","EFO_0002617","Serious","S,O,F",2013
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000130294","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000070018","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Winlevi","Clascoterone","CHEMBL3590187","ENSG00000169083","ENSG00000163565","Cassiopea SpA","Androgen receptor inhibitor","Other indication","Acne vulgaris","acne","EFO_0003894","Not serious","S",2020
"Evenity","Romosozumab","CHEMBL2107874","ENSG00000167941","ENSG00000070018","Amgen","Sclerostin inhibitor","Other indication","Osteoporosis","osteoporosis","EFO_0003882","Not serious","S",2019
"Tecfidera","Dimethyl fumarate","CHEMBL2107333","ENSG00000079999","ENSG00000030582","Biogen Idec","MOA unknown; activates NRF2 pathway","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2013
"Mayzent","Siponimod","CHEMBL2336071","ENSG00000170989","ENSG00000110848","Novartis","S1P receptor modulator","Other indication","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Serious","S",2019
"Vyndaqel","Tafamidis","CHEMBL2103837","ENSG00000118271","ENSG00000026025","Pfizer/Foldrx","Transthyretin stabilizer","Other indication","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Serious","P,O,B,F",2019
"Tepezza","Teprotumumab","CHEMBL1743079","ENSG00000140443","ENSG00000017427","Horizon Therapeutics","IGF1R-directed mAb","Other indication","Thyroid eye disease","Graves disease","EFO_0004237","Not concordant","P,O,B,F",2020
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000134086","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000134086","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000134086","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000134086","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000134086","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000134086","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000134086","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000134086","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000134086","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000096968","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000096968","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000096968","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000096968","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Ocrevus","Ocrelizumab","CHEMBL2108041","ENSG00000156738","ENSG00000168685","Roche/Genentech","CD20-directed cytolytic antibody","Other indication","Relapsing or primary progressive forms of multiple sclerosis","chronic progressive multiple sclerosis","EFO_0003840","Serious","P,B,F",2017
"Empaveli","Pegcetacoplan","CHEMBL4298211","ENSG00000125730","ENSG00000000971","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000185245","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Emflaza","Deflazacort","CHEMBL1201891","ENSG00000113580","ENSG00000146648","PTC Therapeutics","Corticosteroid","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,F",2017
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000160323","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000160323","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000160323","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000160323","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000160323","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000160323","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000160323","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000185010","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Viltepso","Viltolarsen","CHEMBL4298062","ENSG00000198947","ENSG00000101400","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020
"Vyondys 53","Golodirsen","CHEMBL4297762","ENSG00000198947","ENSG00000101400","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019
"Exondys 51","Eteplirsen","CHEMBL2108278","ENSG00000198947","ENSG00000101400","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016
"Amondys 45","Casimersen","CHEMBL4297566","ENSG00000198947","ENSG00000101400","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021
"Viltepso","Viltolarsen","CHEMBL4298062","ENSG00000198947","ENSG00000101400","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020
"Vyondys 53","Golodirsen","CHEMBL4297762","ENSG00000198947","ENSG00000101400","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019
"Exondys 51","Eteplirsen","CHEMBL2108278","ENSG00000198947","ENSG00000101400","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016
"Amondys 45","Casimersen","CHEMBL4297566","ENSG00000198947","ENSG00000101400","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000152256","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000123496","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000123496","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000123496","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000123496","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000123496","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000123496","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Viltepso","Viltolarsen","CHEMBL4298062","ENSG00000198947","ENSG00000171873","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020
"Vyondys 53","Golodirsen","CHEMBL4297762","ENSG00000198947","ENSG00000171873","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019
"Exondys 51","Eteplirsen","CHEMBL2108278","ENSG00000198947","ENSG00000171873","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016
"Amondys 45","Casimersen","CHEMBL4297566","ENSG00000198947","ENSG00000171873","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000141736","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000141736","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Viltepso","Viltolarsen","CHEMBL4298062","ENSG00000198947","ENSG00000138101","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020
"Vyondys 53","Golodirsen","CHEMBL4297762","ENSG00000198947","ENSG00000138101","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019
"Exondys 51","Eteplirsen","CHEMBL2108278","ENSG00000198947","ENSG00000138101","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016
"Amondys 45","Casimersen","CHEMBL4297566","ENSG00000198947","ENSG00000138101","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000111679","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000111679","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000111679","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000111679","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000134352","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000134352","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Emflaza","Deflazacort","CHEMBL1201891","ENSG00000113580","ENSG00000142208","PTC Therapeutics","Corticosteroid","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,F",2017
"Galafold","Migalastat","CHEMBL110458","ENSG00000102393","ENSG00000134243","Amicus Therapeutics","beta-galactosidase regulator","Other indication","Fabry disease","fabry disease","MONDO_0010526","Serious","P,O,A,F",2018
"Viltepso","Viltolarsen","CHEMBL4298062","ENSG00000198947","ENSG00000173402","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020
"Vyondys 53","Golodirsen","CHEMBL4297762","ENSG00000198947","ENSG00000173402","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019
"Exondys 51","Eteplirsen","CHEMBL2108278","ENSG00000198947","ENSG00000173402","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016
"Amondys 45","Casimersen","CHEMBL4297566","ENSG00000198947","ENSG00000173402","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000077238","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Repatha","Evolocumab","CHEMBL2364655","ENSG00000169174","ENSG00000130164","Amgen","PCSK9 inhibitor","Other indication","LDL lowering","LDL cholesterol change measurement","EFO_0007804","Not serious","S,O",2015
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000135766","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000110799","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Cablivi","Caplacizumab","CHEMBL2109624","ENSG00000110799","ENSG00000110799","Sanofi/Ablynx","vWF-directed nanobody","Other indication","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Serious","P,O,F",2019
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000115415","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000115415","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000115415","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000115415","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000159110","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000159110","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000159110","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000159110","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Viltepso","Viltolarsen","CHEMBL4298062","ENSG00000198947","ENSG00000134769","Nippon Shinyaku","Dystrophin splicing modifier","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2020
"Vyondys 53","Golodirsen","CHEMBL4297762","ENSG00000198947","ENSG00000134769","Sarepta","Exon 53 skipping antisense","Other indication","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2019
"Exondys 51","Eteplirsen","CHEMBL2108278","ENSG00000198947","ENSG00000134769","Sarepta Therapeutics","ASO designed to target dystrophin pre-mRNA","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2016
"Amondys 45","Casimersen","CHEMBL4297566","ENSG00000198947","ENSG00000134769","Sarepta","Exon 45-skipping ASO","Other indication","DMD","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,A,F",2021
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000147168","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000147168","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Kevzara","Sarilumab","CHEMBL2108730","ENSG00000160712","ENSG00000136244","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017
"Kevzara","Sarilumab","CHEMBL2108730","ENSG00000160712","ENSG00000136244","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017
"Kevzara","Sarilumab","CHEMBL2108730","ENSG00000160712","ENSG00000136244","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017
"Kevzara","Sarilumab","CHEMBL2108730","ENSG00000160712","ENSG00000137642","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017
"Kevzara","Sarilumab","CHEMBL2108730","ENSG00000160712","ENSG00000137642","Sanofi/Regeneron","IL-6 receptor antagonist","Other indication","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Serious","S",2017
"Empaveli","Pegcetacoplan","CHEMBL4298211","ENSG00000125730","ENSG00000155659","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021
"Empaveli","Pegcetacoplan","CHEMBL4298211","ENSG00000125730","ENSG00000155659","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021
"Emflaza","Deflazacort","CHEMBL1201891","ENSG00000113580","ENSG00000204389","PTC Therapeutics","Corticosteroid","Other indication","Duchenne muscular dystrophy","Duchenne muscular dystrophy","MONDO_0010679","Serious","P,O,F",2017
"Ocrevus","Ocrelizumab","CHEMBL2108041","ENSG00000156738","ENSG00000156738","Roche/Genentech","CD20-directed cytolytic antibody","Other indication","Relapsing or primary progressive forms of multiple sclerosis","chronic progressive multiple sclerosis","EFO_0003840","Serious","P,B,F",2017
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000131724","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000131724","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000131724","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000131724","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000131724","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Adbry","Tralokinumab","CHEMBL1743081","ENSG00000169194","ENSG00000131724","LEO Pharma","IL-13-targeted mAb","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","S",2021
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000131724","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000131724","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Empaveli","Pegcetacoplan","CHEMBL4298211","ENSG00000125730","ENSG00000203710","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021
"Empaveli","Pegcetacoplan","CHEMBL4298211","ENSG00000125730","ENSG00000125730","Apellis","Complement protein C3 inhibitor","Other indication","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Serious","P,O,F",2021
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000168610","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Cibinqo","Abrocitinib","CHEMBL3655081","ENSG00000162434","ENSG00000168610","Pfizer","JAK inhibitor","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2022
"Welireg","Belzutifan","CHEMBL4585668","ENSG00000116016","ENSG00000136878","Merck & Co.","HIF-2alpha inhibitor","Oncology","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Serious","P,O",2021
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000166888","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000166888","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000166888","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000166888","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000166888","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000166888","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000113520","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000113520","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000113520","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000113520","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000113520","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Dupixent","Dupilumab","CHEMBL2108675","ENSG00000077238","ENSG00000113520","Regeneron/Sanofi","IL-4Ralpha antagonist","Other indication","Atopic dermatitis","atopic eczema","EFO_0000274","Not serious","P,B",2017
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000111640","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000145675","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000111640","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000176105","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000176105","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000170276","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137801","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tezspire","Tezepelumab","CHEMBL3707229","ENSG00000145777","ENSG00000269335","Astrazeneca/Amgen","TSLP-targeted mAb","Other indication","Serious asthma","asthma","MONDO_0004979","Serious","P",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000068001","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000147955","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000147955","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000165025","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000012817","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000012817","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000134243","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000183098","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000167548","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000167548","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000167548","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000167548","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000167548","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000167548","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000117450","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000117450","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000011132","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000132589","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000140941","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000140941","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000110092","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000110092","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000110092","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000110092","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000110092","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000110092","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000010017","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000160307","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000160307","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000117984","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000151694","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000188157","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000120899","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000124145","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000124145","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000120899","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000145675","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000145675","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000145675","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000145675","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000145675","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000145675","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000145675","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000145675","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000277586","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000277586","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000115041","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000161011","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000169783","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000197122","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000197122","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000197122","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000197122","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000197122","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000197122","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000198400","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000278195","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000132437","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000132437","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000182240","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000198805","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000125686","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000125686","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000002330","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000169884","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000084234","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000113575","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000158828","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000256762","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000084234","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000113575","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000158828","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000154096","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000154096","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137642","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000122861","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137642","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000184144","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137642","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137642","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137642","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137642","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137642","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137642","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137642","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000000938","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000000938","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000168036","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000168036","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000168036","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000168036","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000168036","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000168036","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000168036","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000168036","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000168036","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000168036","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000108468","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000109971","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000163932","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143933","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000014216","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000120885","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000120885","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000120885","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000014216","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000072062","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000132773","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000167004","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Motegrity","Prucalopride","CHEMBL117287","ENSG00000164270","ENSG00000164270","Shire/Takeda","5-HT4-receptor agonist","Other indication","Chronic idiopathic constipation","constipation disorder","MONDO_0002203","Not serious","S",2018
"Saphnelo","Anifrolumab","CHEMBL2364653","ENSG00000142166","ENSG00000072803","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196531","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000197386","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196531","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000049540","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000113140","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000118271","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142156","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196230","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000157450","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196230","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000124214","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000221914","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000113805","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000139318","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000123384","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000135218","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000130522","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000130522","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000170348","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000010671","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000010671","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000010671","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000010671","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137463","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000134853","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000140396","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000140396","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000140396","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000140396","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000159593","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000159593","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000141433","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000160695","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000141433","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000134954","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000134954","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000114646","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000180210","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000114646","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000254087","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000254087","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000254087","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000254087","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000105851","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000134318","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000151224","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000121691","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000150093","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000121691","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000150093","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000175344","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000179218","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000175344","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000128482","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000133858","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000123560","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000126214","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137752","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000123560","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000126214","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000185933","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000065320","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000141551","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000101439","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000101439","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000101439","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196549","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000204301","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000132703","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000136156","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000182866","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000182866","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000182866","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000182866","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000124151","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000124151","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000182866","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000182866","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000232810","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000232810","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000128989","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000136827","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000166949","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000186868","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000128989","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000186868","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000186868","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000105376","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000204305","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000204305","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000144339","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000148082","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196776","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000138095","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000144339","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196776","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000132692","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000080824","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000101204","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000102974","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000205302","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000101204","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000165025","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000165025","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000179295","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000179295","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000165025","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000165025","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000179295","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000179295","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000156475","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000156475","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000183775","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000157404","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000163879","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000165025","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000165025","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000054523","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000130234","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000153234","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196712","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tezspire","Tezepelumab","CHEMBL3707229","ENSG00000145777","ENSG00000171867","Astrazeneca/Amgen","TSLP-targeted mAb","Other indication","Serious asthma","asthma","MONDO_0004979","Serious","P",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000054523","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000119912","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000123143","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Saphnelo","Anifrolumab","CHEMBL2364653","ENSG00000142166","ENSG00000105397","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021
"Saphnelo","Anifrolumab","CHEMBL2364653","ENSG00000142166","ENSG00000105397","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021
"Saphnelo","Anifrolumab","CHEMBL2364653","ENSG00000142166","ENSG00000105397","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000165916","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000170315","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000165916","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000165916","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Besponsa","Inotuzumab ozogamicin","CHEMBL2108611","ENSG00000012124","ENSG00000254087","Pfizer","CD22-directed antibodydrug conjugate","Oncology","B cell precursor ALL","precursor B-cell acute lymphoblastic leukemia","MONDO_0020511","Serious","P,O,B",2017
"Besponsa","Inotuzumab ozogamicin","CHEMBL2108611","ENSG00000012124","ENSG00000254087","Pfizer","CD22-directed antibodydrug conjugate","Oncology","B cell precursor ALL","precursor B-cell acute lymphoblastic leukemia","MONDO_0020511","Serious","P,O,B",2017
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000188517","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196924","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000168610","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000204843","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000168610","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000136826","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000136826","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Saphnelo","Anifrolumab","CHEMBL2364653","ENSG00000142166","ENSG00000170581","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000136826","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000136826","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Saphnelo","Anifrolumab","CHEMBL2364653","ENSG00000142166","ENSG00000170581","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000136826","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000136826","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000171132","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000176884","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000171132","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000176884","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000141867","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000141867","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000141867","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000141867","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000141867","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000141867","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000130522","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000130522","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000141867","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000141867","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000144381","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000067225","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196136","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000198959","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000075651","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137845","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137845","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137845","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137845","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143369","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000157766","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000067560","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000067560","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000175104","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000078549","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000134259","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000158560","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000101266","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000167037","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000185345","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000134287","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000080815","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000080815","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000241837","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000080815","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000080815","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000080815","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000080815","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000080815","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000101213","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000101213","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000101213","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000101213","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000101213","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000101213","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000106211","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000113721","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000171049","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000106211","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000113721","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000141646","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000181773","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000073060","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000073060","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000128052","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000131508","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000139182","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000131508","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000124181","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000124181","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000124181","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000189403","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000239697","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000157554","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000157554","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000157554","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000157554","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000157554","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000157554","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000136504","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000136504","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000136504","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000136504","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143801","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000076248","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000108387","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000124788","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000135823","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143801","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000135823","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143801","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143801","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000110395","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000141027","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000141027","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000141027","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000141027","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000141027","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000141027","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000130066","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000113721","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000113721","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000113721","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000113721","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000069329","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000088832","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000154277","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000162604","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000176697","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000275700","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000154277","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000176697","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000069696","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000120948","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000170345","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000120948","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000069696","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000106462","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000106462","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000106462","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000106462","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000106462","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000106462","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000145715","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000145715","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000145715","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000145715","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000169083","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000169083","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000096063","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000197461","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000160691","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000160691","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000160691","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000160691","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000126934","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000157212","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000147224","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Sylvant","Siltuximab","CHEMBL1743070","ENSG00000136244","ENSG00000160712","Janssen Biotech","IL-6-specific antibody","Other indication","Multicentric Castleman's disease","Castleman disease","MONDO_0015564","Serious","P,O",2014
"Sylvant","Siltuximab","CHEMBL1743070","ENSG00000136244","ENSG00000160712","Janssen Biotech","IL-6-specific antibody","Other indication","Multicentric Castleman's disease","Castleman disease","MONDO_0015564","Serious","P,O",2014
"Tazverik","Tazemetostat","CHEMBL3414621","ENSG00000106462","ENSG00000085224","Epizyme","EZH2 inhibitor","Oncology","Epithelioid sarcoma","epithelioid sarcoma","MONDO_0017387","Serious","P,O,A,F",2020
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000184203","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000168077","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000168077","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000198804","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000112592","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Saphnelo","Anifrolumab","CHEMBL2364653","ENSG00000142166","ENSG00000115415","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021
"Saphnelo","Anifrolumab","CHEMBL2364653","ENSG00000142166","ENSG00000115415","AstraZeneca","IFNAR-targeted mAb","Other indication","SLE","systemic lupus erythematosus","MONDO_0007915","Serious","S,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000101412","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000116141","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000123416","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000253729","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000253729","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000109501","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000109501","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000184702","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000148180","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000148180","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000097007","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000097007","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000097007","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000097007","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000097007","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000097007","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000266412","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000266412","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000266412","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000266412","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142192","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000121653","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142192","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000146072","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142192","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000066027","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142192","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142192","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142192","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142192","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000121653","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142192","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142192","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000184634","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000184634","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000184634","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000184634","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000184634","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000184634","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000184634","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000184634","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000116288","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000116288","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000087245","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000124222","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000172977","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000134709","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000148798","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000148798","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000141968","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000141968","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000062725","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000198736","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000108179","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000116133","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000116133","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000158792","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000109685","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000109685","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000007047","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000163697","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000175582","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000102030","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000175582","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000007047","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Gamifant","Emapalumab","CHEMBL3989977","ENSG00000111537","ENSG00000027697","Novimmune","Interferon--blocking antibody","Other indication","Primary haemophagocytic lymphohistiocytosis","genetic hemophagocytic lymphohistiocytosis","MONDO_0015541","Serious","P,O,B",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000044574","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000145431","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000167552","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000177606","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000178127","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000177606","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000108578","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000177426","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000063660","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000092969","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000115414","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000115414","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000162711","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000162711","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000070748","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000127445","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000127445","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000101336","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000101336","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000168484","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000171603","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000005339","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000005339","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000005339","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000005339","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000005339","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000005339","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000146731","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000148400","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000135077","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000034053","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000132155","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000132155","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000118058","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000118058","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000118058","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000118058","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000118058","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000118058","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000104805","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000166033","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000197442","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000166033","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000168610","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000072506","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Viberzi","Eluxadoline","CHEMBL2159122","ENSG00000112038","ENSG00000172243","Allergan","Mu-opioid receptor agonist","Other indication","Irritable bowel syndrome","irritable bowel syndrome","EFO_0000555","Not serious","P,F",2015
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000105329","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000132535","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000132535","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000100285","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000100285","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000100311","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000100311","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000100311","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000100311","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000100311","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000171867","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000084676","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000084676","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000084676","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000084676","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000135018","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000135018","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000075624","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000100985","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000164402","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000075624","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000102879","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000164402","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000105974","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000178741","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000105974","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000178741","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000065154","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000103415","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000129219","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143153","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000146648","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000065154","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000103415","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143153","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000146648","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000129219","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000159388","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000159388","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000159388","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000159388","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000102003","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000172115","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000169604","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000106617","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000157168","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000204264","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000157168","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137312","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000147257","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000116288","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000116288","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000089280","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000089280","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000089280","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000089280","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000129514","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000129514","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000129514","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000129514","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000129514","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000129514","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000129514","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000129514","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000210082","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000125977","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000006125","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143514","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000172059","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143514","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000164305","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000204209","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000204209","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000204209","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000204209","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000109846","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000113108","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000100030","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000185825","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000185825","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000011465","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000172020","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000179399","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000242689","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000011465","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000172020","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000004478","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000004478","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000160691","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000138798","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000163956","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000168385","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000152256","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000163956","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000182511","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000182511","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000019169","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000109099","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000109099","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000124181","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000124181","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000124181","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000124181","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000120910","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000115884","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000100083","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000134215","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000134215","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137947","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000137947","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000169083","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000169083","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000064300","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000095970","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000171791","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000171791","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000146648","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000146648","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000146648","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000012124","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000012124","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000107959","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000071242","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000107959","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196535","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143870","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000166313","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000166598","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000143870","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000166598","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000107282","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000188313","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000173020","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000170312","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000204463","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000117362","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000102466","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000117362","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000127824","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000127824","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000173406","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000122194","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000145335","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000145335","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000145335","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000105290","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000068024","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000068024","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000068024","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000068024","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000130203","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000130203","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000162236","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000196262","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000130203","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000130203","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000130203","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000138613","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000138613","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000138613","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Tavalisse","Fostamatinib","CHEMBL2103830","ENSG00000165025","ENSG00000142192","Rigel Pharmaceuticals","SYK inhibitor","Other indication","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Serious","S,O",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000123080","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000182871","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000157005","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000157005","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000117461","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000117461","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000142515","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000142515","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000142515","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000142515","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000167755","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000167772","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000111237","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000187554","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000111237","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000160014","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000166851","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000160014","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000143322","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000143322","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000196363","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000196363","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000105723","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000197971","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000125848","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000197971","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000105723","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000127022","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000136854","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000136854","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000172531","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000140564","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000105647","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000105647","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000064012","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000164885","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000164885","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000164885","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000142875","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000186318","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000205155","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000186318","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000205155","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000070808","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000108443","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000070808","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000167193","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000074317","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000141434","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000138449","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000138449","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000168702","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000168702","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000051128","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000089685","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000184937","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000010810","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000168615","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000010810","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Nubeqa","Darolutamide","CHEMBL4297185","ENSG00000169083","ENSG00000136573","Bayer","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2019
"Erleada","Apalutamide","CHEMBL3183409","ENSG00000169083","ENSG00000136573","Johnson & Johnson","Androgen receptor inhibitor","Oncology","Prostate cancer","prostate cancer","MONDO_0008315","Serious","P,F",2018
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000082701","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000099250","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000082701","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000099250","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000082701","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Lartruvo","Olaratumab","CHEMBL1743049","ENSG00000134853","ENSG00000099942","Eli Lilly","PDGFRalpha-blocking antibody","Oncology","Soft tissue sarcoma","soft tissue sarcoma","EFO_1001968","Serious","P,O,B,A,F",2016
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000131042","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000131042","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000138685","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000144711","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000241563","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000118137","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000131187","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000133961","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000254087","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Aduhelm","Aducanumab","CHEMBL3039540","ENSG00000142192","ENSG00000254087","Biogen/Eisai","Amyloid-beta-targeted mAb","Other indication","Alzheimers disease","Alzheimers disease","MONDO_0004975","Serious","P,A,F",2021
"Poteligeo","Mogamulizumab","CHEMBL1743041","ENSG00000183813","ENSG00000102970","Kyowa Hakko Kirin","CCR4 antibody","Oncology","mycosis fungoides or Sezary syndrome","mycosis fungoides","EFO_1001051","Serious","P,O,B",2018
"Leqvio","Inclisiran","CHEMBL3990033","ENSG00000169174","ENSG00000130164","Novartis/Alnylam","PCSK9-targeted siRNA","Other indication","HeFH or ASCVD","coronary atherosclerosis","MONDO_0021661","Serious","S",2021
"Leqvio","Inclisiran","CHEMBL3990033","ENSG00000169174","ENSG00000130164","Novartis/Alnylam","PCSK9-targeted siRNA","Other indication","HeFH or ASCVD","coronary atherosclerosis","MONDO_0021661","Serious","S",2021
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000100368","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000197386","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Macrilen","Macimorelin","CHEMBL278623","ENSG00000121853","ENSG00000121853","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017
"Macrilen","Macimorelin","CHEMBL278623","ENSG00000121853","ENSG00000121853","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017
"Macrilen","Macimorelin","CHEMBL278623","ENSG00000121853","ENSG00000121853","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017
"Macrilen","Macimorelin","CHEMBL278623","ENSG00000121853","ENSG00000121853","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017
"Macrilen","Macimorelin","CHEMBL278623","ENSG00000121853","ENSG00000121853","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017
"Macrilen","Macimorelin","CHEMBL278623","ENSG00000121853","ENSG00000121853","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000169047","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000169047","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000169047","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Givlaari","Givosiran","CHEMBL4297760","ENSG00000023330","ENSG00000023330","Alnylam","ALAS1-directed siRNA","Other indication","Acute hepatic porphyria","acute hepatic porphyria","Orphanet_95157","Serious","P,O,B",2019
"Givlaari","Givosiran","CHEMBL4297760","ENSG00000023330","ENSG00000023330","Alnylam","ALAS1-directed siRNA","Other indication","Acute hepatic porphyria","acute hepatic porphyria","Orphanet_95157","Serious","P,O,B",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000177885","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000177885","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Myalept","Metreleptin","CHEMBL2107857","ENSG00000116678","ENSG00000174697","Amylin","Leptin analogue","Other indication","Leptin deficiency in patients with congenital or acquired generalized lipodystrophy","congenital generalized lipodystrophy","EFO_1000681","Serious","P,O,F",2014
"Myalept","Metreleptin","CHEMBL2107857","ENSG00000116678","ENSG00000174697","Amylin","Leptin analogue","Other indication","Leptin deficiency in patients with congenital or acquired generalized lipodystrophy","congenital generalized lipodystrophy","EFO_1000681","Serious","P,O,F",2014
"Jemperli","Dostarlimab","CHEMBL4298124","ENSG00000188389","ENSG00000179295","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021
"Jemperli","Dostarlimab","CHEMBL4298124","ENSG00000188389","ENSG00000179295","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021
"Jemperli","Dostarlimab","CHEMBL4298124","ENSG00000188389","ENSG00000179295","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021
"Jemperli","Dostarlimab","CHEMBL4298124","ENSG00000188389","ENSG00000197646","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000105647","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000105647","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Mulpleta","Lusutrombopag","CHEMBL2107831","ENSG00000117400","ENSG00000096968","Shionogi","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P,F",2018
"Doptelet","Avatrombopag","CHEMBL2103883","ENSG00000117400","ENSG00000096968","Dova Pharmaceuticals","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P",2018
"Mulpleta","Lusutrombopag","CHEMBL2107831","ENSG00000117400","ENSG00000096968","Shionogi","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P,F",2018
"Doptelet","Avatrombopag","CHEMBL2103883","ENSG00000117400","ENSG00000096968","Dova Pharmaceuticals","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P",2018
"Mulpleta","Lusutrombopag","CHEMBL2107831","ENSG00000117400","ENSG00000096968","Shionogi","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P,F",2018
"Doptelet","Avatrombopag","CHEMBL2103883","ENSG00000117400","ENSG00000096968","Dova Pharmaceuticals","Thrombopoietin receptor agonist","Other indication","Thrombocytopenia","thrombocytopenia","HP_0001873","Not concordant","P",2018
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000066427","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Jemperli","Dostarlimab","CHEMBL4298124","ENSG00000188389","ENSG00000120217","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021
"Jemperli","Dostarlimab","CHEMBL4298124","ENSG00000188389","ENSG00000120217","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021
"Jemperli","Dostarlimab","CHEMBL4298124","ENSG00000188389","ENSG00000120217","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021
"Takhzyro","Lanadelumab","CHEMBL3545189","ENSG00000164344","ENSG00000113889","Dyax/Shire","Kallikrein antibody","Other indication","Hereditary angioedema","hereditary angioedema","MONDO_0019623","Serious","P,O,B,F",2018
"Orladeyo","Berotralstatc","CHEMBL4594271","ENSG00000164344","ENSG00000113889","BioCryst","Plasma kallikrein inhibitor","#N/A","Hereditary angioedema","hereditary angioedema","MONDO_0019623","Serious","S,O,F",2020
"Jemperli","Dostarlimab","CHEMBL4298124","ENSG00000188389","ENSG00000006125","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000170145","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000124788","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Jemperli","Dostarlimab","CHEMBL4298124","ENSG00000188389","ENSG00000121594","GlaxoSmithKline","PD1-targeted mAb","Oncology","Endometrial cancer","endometrial cancer","MONDO_0011962","Serious","P,B,A",2021
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000121879","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Sogroya","Somapacitan","CHEMBL3707290","ENSG00000112964","ENSG00000112964","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020
"Sogroya","Somapacitan","CHEMBL3707290","ENSG00000112964","ENSG00000112964","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020
"Sogroya","Somapacitan","CHEMBL3707290","ENSG00000112964","ENSG00000112964","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020
"Sogroya","Somapacitan","CHEMBL3707290","ENSG00000112964","ENSG00000112964","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020
"Sogroya","Somapacitan","CHEMBL3707290","ENSG00000112964","ENSG00000112964","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000117461","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000145675","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000117461","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000145675","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000145675","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000117461","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000145675","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000117461","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000117461","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000145675","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Myalept","Metreleptin","CHEMBL2107857","ENSG00000116678","ENSG00000179295","Amylin","Leptin analogue","Other indication","Leptin deficiency in patients with congenital or acquired generalized lipodystrophy","congenital generalized lipodystrophy","EFO_1000681","Serious","P,O,F",2014
"Myalept","Metreleptin","CHEMBL2107857","ENSG00000116678","ENSG00000116678","Amylin","Leptin analogue","Other indication","Leptin deficiency in patients with congenital or acquired generalized lipodystrophy","congenital generalized lipodystrophy","EFO_1000681","Serious","P,O,F",2014
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000170345","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000065361","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000065361","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000065361","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000065361","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000065361","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Piqray","Alpelisib","CHEMBL2396661","ENSG00000121879","ENSG00000065361","Novartis","PI3K inhibitor","Oncology","Breast cancer","breast cancer","MONDO_0007254","Serious","P",2019
"Skytrofa","Lonapegsomatropin","CHEMBL4298185","ENSG00000112964","ENSG00000259384","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021
"Leqvio","Inclisiran","CHEMBL3990033","ENSG00000169174","ENSG00000169174","Novartis/Alnylam","PCSK9-targeted siRNA","Other indication","HeFH or ASCVD","coronary atherosclerosis","MONDO_0021661","Serious","S",2021
"Corlanor","Ivabradine","CHEMBL471737","ENSG00000138622","ENSG00000138622","Amgen","Hyperpolarization-activated cyclic nucleotide-gated channel blocker","Other indication","Chronic heart failure","Abnormality of the cardiovascular system","HP_0001626","Serious","P,F",2015
"Corlanor","Ivabradine","CHEMBL471737","ENSG00000138622","ENSG00000138622","Amgen","Hyperpolarization-activated cyclic nucleotide-gated channel blocker","Other indication","Chronic heart failure","Abnormality of the cardiovascular system","HP_0001626","Serious","P,F",2015
"Corlanor","Ivabradine","CHEMBL471737","ENSG00000138622","ENSG00000138622","Amgen","Hyperpolarization-activated cyclic nucleotide-gated channel blocker","Other indication","Chronic heart failure","Abnormality of the cardiovascular system","HP_0001626","Serious","P,F",2015
"Skytrofa","Lonapegsomatropin","CHEMBL4298185","ENSG00000112964","ENSG00000112964","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021
"Skytrofa","Lonapegsomatropin","CHEMBL4298185","ENSG00000112964","ENSG00000112964","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021
"Skytrofa","Lonapegsomatropin","CHEMBL4298185","ENSG00000112964","ENSG00000112964","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021
"Skytrofa","Lonapegsomatropin","CHEMBL4298185","ENSG00000112964","ENSG00000112964","Ascendis Pharma","PEGylated human growth hormone","Other indication","Growth failure due to GHD","Growth delay","HP_0001510","Not serious","S,O",2021
"Macrilen","Macimorelin","CHEMBL278623","ENSG00000121853","ENSG00000116678","Aeterna Zentaris","Growth hormone secretagogue receptor agonist","Other indication","Diagnosis of adult growth hormone deficiency","short stature due to GHSR deficiency","MONDO_0014403","Not serious","S,O",2017
"Sogroya","Somapacitan","CHEMBL3707290","ENSG00000112964","ENSG00000196396","Novo Nordisk","Growth hormone analogue","Other indication","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Not serious","S",2020
"Odomzo","Sonidegib","CHEMBL2105737","ENSG00000128602","ENSG00000185920","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015
"Odomzo","Sonidegib","CHEMBL2105737","ENSG00000128602","ENSG00000185920","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015
"Odomzo","Sonidegib","CHEMBL2105737","ENSG00000128602","ENSG00000185920","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015
"Odomzo","Sonidegib","CHEMBL2105737","ENSG00000128602","ENSG00000185920","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015
"Odomzo","Sonidegib","CHEMBL2105737","ENSG00000128602","ENSG00000185920","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015
"Odomzo","Sonidegib","CHEMBL2105737","ENSG00000128602","ENSG00000185920","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015
"Odomzo","Sonidegib","CHEMBL2105737","ENSG00000128602","ENSG00000185920","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015
"Odomzo","Sonidegib","CHEMBL2105737","ENSG00000128602","ENSG00000185920","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015
"Odomzo","Sonidegib","CHEMBL2105737","ENSG00000128602","ENSG00000185920","Novartis","Smoothened inhibitor","Oncology","Basal cell carcinoma","basal cell carcinoma","EFO_0004193","Not serious","S",2015
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000113013","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000126934","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000108953","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000126934","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000126934","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000126934","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000126934","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000108953","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000126934","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000078061","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000078061","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000078061","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000078061","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000078061","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000095015","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000095015","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000095015","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000095015","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000099250","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000010610","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000010610","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000010610","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Jeuveau","Prabotulinumtoxin A","CHEMBL4297229","ENSG00000132639","ENSG00000220205","Evolus","Acetylcholine release inhibitor and a neuromuscular blocking agent","Other indication","Glabellar lines associated with corrugator and/or procerus muscle activity","Facial wrinkling","HP_0009762","Not serious","S",2019
"Daxxify","DaxibotulinumtoxinA","CHEMBL3707359","ENSG00000132639","ENSG00000220205","Revance","Botulinum toxin","Other indication","Glabellar lines","Facial wrinkling","HP_0009762","Not serious","S",2022
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000160691","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000067225","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000067225","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000157764","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000157764","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000157764","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000157764","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000157764","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000157764","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000157764","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000157764","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000142192","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000044574","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000037280","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000037280","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000037280","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000109971","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000109971","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000186432","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000133703","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000133703","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000133703","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000133703","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000133703","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000150630","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000142798","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000182866","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000182866","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000100097","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000213281","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000213281","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000213281","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000213281","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000213281","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000213281","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000112715","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000112715","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000140575","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000169032","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000169032","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000169032","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000169032","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000169032","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000169032","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000169032","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Kimmtrak","Tebentafusp","CHEMBL4297990","ENSG00000185664","ENSG00000185664","Immunocore","gp100 peptide HLA _ CD3 bispecific T-cell engager","Oncology","Uveal melanoma","Uveal Melanoma","EFO_1000616","Serious","P,O,B",2022
"Kimmtrak","Tebentafusp","CHEMBL4297990","ENSG00000185664","ENSG00000185664","Immunocore","gp100 peptide HLA _ CD3 bispecific T-cell engager","Oncology","Uveal melanoma","Uveal Melanoma","EFO_1000616","Serious","P,O,B",2022
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000187555","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000174775","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000174775","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000174775","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000174775","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000174775","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000132155","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000132155","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000132155","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000132155","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000132155","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000132155","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000132155","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000157193","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000128052","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000128052","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000128052","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000128052","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000128052","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000171132","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000171132","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000171132","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000179776","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000179776","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000096384","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000164924","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000096384","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000096384","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000096384","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000096384","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000141564","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000105401","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000197122","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000197122","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000197122","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000160791","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000160791","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000160791","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000160791","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000160791","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Trogarzo","Ibalizumab","CHEMBL1743029","ENSG00000010610","ENSG00000160791","TaiMed Biologics/Theratechnologies","CD4 antibody","Other indication","HIV","hiv infection","EFO_0000764","Serious","P,O,B,F",2018
"Cyramza","Ramucirumab","CHEMBL1743062","ENSG00000128052","ENSG00000111679","Eli Lilly","VEGFR2 antagonist","Oncology","Gastric cancer","gastric cancer","MONDO_0001056","Serious","P,O,F",2014
"Jeuveau","Prabotulinumtoxin A","CHEMBL4297229","ENSG00000132639","ENSG00000132639","Evolus","Acetylcholine release inhibitor and a neuromuscular blocking agent","Other indication","Glabellar lines associated with corrugator and/or procerus muscle activity","Facial wrinkling","HP_0009762","Not serious","S",2019
"Daxxify","DaxibotulinumtoxinA","CHEMBL3707359","ENSG00000132639","ENSG00000132639","Revance","Botulinum toxin","Other indication","Glabellar lines","Facial wrinkling","HP_0009762","Not serious","S",2022
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000166913","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Braftovi","Encorafenib","CHEMBL3301612","ENSG00000157764","ENSG00000166913","Array BioPharma","BRAF inhibitor","Oncology","BRAF-mutated melanoma","melanoma","EFO_0000756","Serious","S,O",2018
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000081237","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000081237","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000123983","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000123983","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000153201","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000153201","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000162434","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000162434","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000080824","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000080824","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000105976","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000105976","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000105976","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000105976","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000105976","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000105976","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000005700","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000005700","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000005700","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000179295","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000179295","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000178568","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000178568","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000117560","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000117560","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000117560","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000117560","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000117560","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000117560","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000169083","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000169083","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000169083","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000169083","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000169083","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000169083","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000117461","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000117461","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000117461","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000117461","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000117461","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000117461","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000142192","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000142192","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000010671","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000010671","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000010671","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000010671","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000010671","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000010671","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000010671","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000010671","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000010671","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000010671","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000010671","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000010671","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000082898","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000082898","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000116017","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000116017","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000116017","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000168610","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000168610","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000096384","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000096384","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000096384","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Brukinsa","Zanubrutinib","CHEMBL3936761","ENSG00000010671","ENSG00000096384","BeiGene","BTK inhibitor","Oncology","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A,F",2019
"Imbruvica","Ibrutinib","CHEMBL1873475","ENSG00000010671","ENSG00000096384","Pharmacyclics","Bruton's tyrosine kinase inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,F",2013
"Calquence","Acalabrutinib","CHEMBL3707348","ENSG00000010671","ENSG00000096384","AstraZeneca/Acerta Pharma","BTK inhibitor","Oncology","Mantle cell lymphoma","Mantle cell lymphoma","EFO_1001469","Serious","P,O,B,A",2017
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000085832","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000085832","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000197122","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000197122","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000127329","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000127329","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000145675","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000145675","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000165025","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000165025","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000146648","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000146648","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000072274","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000072274","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000096384","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000096384","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000163399","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000163399","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000143322","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000143322","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000157168","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000157168","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000065361","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000065361","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000101213","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000101213","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000135605","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000135605","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000204305","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000204305","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000152894","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000152894","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000141736","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000141736","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000141736","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000141736","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000118271","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000118271","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000118271","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000118271","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000118271","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000118271","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000118271","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000118271","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000118271","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000118271","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000118271","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000118271","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000118271","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000118271","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000118271","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000118271","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Onpattro","Patisiran","CHEMBL3989987","ENSG00000118271","ENSG00000118271","Alnylam Pharmaceuticals","TTR-directed small interfering RNA","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,B,F",2018
"Tegsedi","Inotersen","CHEMBL4297770","ENSG00000118271","ENSG00000118271","Ionis Pharmaceuticals","TTR-directed antisense oligonucleotide","Other indication","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Serious","P,O,F",2018
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000111252","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000111252","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000113263","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000113263","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Crysvita","Burosumab","CHEMBL3707326","ENSG00000118972","ENSG00000077782","Ultragenyx Pharmaceutical/Kyowa Hakko Kirin","FGF23 antibody","Other indication","X-linked hypophosphataemia","Hypophosphatemia","HP_0002148","Not serious","P,O,B,F",2018
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000124181","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000124181","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Bavencio","Avelumab","CHEMBL3833373","ENSG00000120217","ENSG00000197646","Merck KGaA/Pfizer","PDL1-blocking antibody","Oncology","Merkel cell carcinoma","Merkel cell skin cancer","EFO_1001471","Serious","P,O,B,A,F",2017
"Bavencio","Avelumab","CHEMBL3833373","ENSG00000120217","ENSG00000188389","Merck KGaA/Pfizer","PDL1-blocking antibody","Oncology","Merkel cell carcinoma","Merkel cell skin cancer","EFO_1001471","Serious","P,O,B,A,F",2017
"Bavencio","Avelumab","CHEMBL3833373","ENSG00000120217","ENSG00000188389","Merck KGaA/Pfizer","PDL1-blocking antibody","Oncology","Merkel cell carcinoma","Merkel cell skin cancer","EFO_1001471","Serious","P,O,B,A,F",2017
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000097007","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000097007","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
"Sotyktu","Deucravacitinib","CHEMBL4435170","ENSG00000105397","ENSG00000170581","Bristol Myers Squibb","TYK2 inhibitor","Other indication","Plaque psoriasis","psoriasis vulgaris","EFO_1001494","Not serious","S",2022
"Sotyktu","Deucravacitinib","CHEMBL4435170","ENSG00000105397","ENSG00000170581","Bristol Myers Squibb","TYK2 inhibitor","Other indication","Plaque psoriasis","psoriasis vulgaris","EFO_1001494","Not serious","S",2022
"Tukysa","Tucatinib","CHEMBL3989868","ENSG00000141736","ENSG00000141968","Seagen","HER2 kinase inhibitor","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","P,O,B,F",2020
"Margenza","Margetuximab","CHEMBL2364649","ENSG00000141736","ENSG00000141968","MacroGenics","HER2-directed mAb","Oncology","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Serious","S,F",2020
